153 related articles for article (PubMed ID: 36310147)
1. Imidazolylpyrrolone-Based Small Molecules as Anticancer Agents for Renal Cell Carcinoma.
Sousa A; Pontes O; Andrade J; Baltazar F; Costa M; Proença F
ChemMedChem; 2023 Jan; 18(2):e202200519. PubMed ID: 36310147
[TBL] [Abstract][Full Text] [Related]
2. A Simple Precursor for Highly Functionalized Fused Imidazo[4,5-b]pyridines and Imidazo[4,5-b]-1,8-naphthyridine.
Al-Duaij OK; Zaki ME; El Gazzar AB
Molecules; 2016 Dec; 21(12):. PubMed ID: 27916964
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
[TBL] [Abstract][Full Text] [Related]
4. Efficient synthesis of 3H-imidazo[4,5-b]pyridines from malononitrile and 5-amino-4-(cyanoformimidoyl)imidazoles.
Zaki ME; Proença MF; Booth BL
J Org Chem; 2003 Jan; 68(2):276-82. PubMed ID: 12530849
[TBL] [Abstract][Full Text] [Related]
5. Exploration of imidazole and imidazopyridine dimers as anticancer agents: Design, synthesis, and structure-activity relationship study.
Meenakshisundaram S; Manickam M; Pillaiyar T
Arch Pharm (Weinheim); 2019 Dec; 352(12):e1900011. PubMed ID: 31596021
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of potential anticancer agents: imidazo[4,5-c]pyridines and imidazo[4,5-b]pyridines.
Temple C; Rose JD; Comber RN; Rener GA
J Med Chem; 1987 Oct; 30(10):1746-51. PubMed ID: 3656351
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel indolyl-1,2,4-triazole hybrids as potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with potential anti-renal cancer activity.
Al-Hussain SA; Farghaly TA; Zaki MEA; Abdulwahab HG; Al-Qurashi NT; Muhammad ZA
Bioorg Chem; 2020 Dec; 105():104330. PubMed ID: 33038552
[TBL] [Abstract][Full Text] [Related]
8. Novel 2-indolinone thiazole hybrids as sunitinib analogues: Design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity.
Mahmoud HK; Farghaly TA; Abdulwahab HG; Al-Qurashi NT; Shaaban MR
Eur J Med Chem; 2020 Dec; 208():112752. PubMed ID: 32947227
[TBL] [Abstract][Full Text] [Related]
9. Signaling inhibitors in metastatic renal cell carcinoma.
Escudier B
Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
[TBL] [Abstract][Full Text] [Related]
10. 2,6-Disubstituted imidazo[2,1-b][1,3,4]thiadiazoles: search for anticancer agents.
Noolvi MN; Patel HM; Kamboj S; Kaur A; Mann V
Eur J Med Chem; 2012 Oct; 56():56-69. PubMed ID: 22960694
[TBL] [Abstract][Full Text] [Related]
11. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
[TBL] [Abstract][Full Text] [Related]
12. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapies in metastatic renal cancer in 2009.
Bastien L; Culine S; Paule B; Ledbai S; Patard JJ; de la Taille A
BJU Int; 2009 May; 103(10):1334-42. PubMed ID: 19338565
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, in vitro anticancer evaluation and in silico studies of novel imidazo[2,1-b]thiazole derivatives bearing pyrazole moieties.
Ali AR; El-Bendary ER; Ghaly MA; Shehata IA
Eur J Med Chem; 2014 Mar; 75():492-500. PubMed ID: 24576591
[TBL] [Abstract][Full Text] [Related]
15. Tilting the AXIS towards therapeutic limits in renal cancer.
Bex A; Haanen J
Lancet; 2011 Dec; 378(9807):1898-900. PubMed ID: 22056245
[No Abstract] [Full Text] [Related]
16. Various forms of HIF-1α protein characterize the clear cell renal cell carcinoma cell lines.
Swiatek M; Jancewicz I; Kluebsoongnoen J; Zub R; Maassen A; Kubala S; Udomkit A; Siedlecki JA; Sarnowski TJ; Sarnowska E
IUBMB Life; 2020 Jun; 72(6):1220-1232. PubMed ID: 32250548
[TBL] [Abstract][Full Text] [Related]
17. Selective Cytotoxicity of Portuguese Propolis Ethyl Acetate Fraction towards Renal Cancer Cells.
Freitas AS; Costa M; Pontes O; Seidel V; Proença F; Cardoso SM; Oliveira R; Baltazar F; Almeida-Aguiar C
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807247
[TBL] [Abstract][Full Text] [Related]
18. Combined Treatment with CCI779 and SB203580 Induces Cellular Senescence in Renal Cell Carcinoma Cell Line via p53 Pathway.
Chauhan A; Ojha R; Semwal DK; Mishra SP; Semwal RB
Anticancer Agents Med Chem; 2017 Nov; 17(11):1545-1554. PubMed ID: 28270077
[TBL] [Abstract][Full Text] [Related]
19. New imidazo[2,1-b]thiazole derivatives: synthesis, in vitro anticancer evaluation, and in silico studies.
Park JH; El-Gamal MI; Lee YS; Oh CH
Eur J Med Chem; 2011 Dec; 46(12):5769-77. PubMed ID: 22033063
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of novel imidazo[4,5-b]pyridine based compounds as potent anticancer agents with CDK9 inhibitory activity.
Ghanem NM; Farouk F; George RF; Abbas SES; El-Badry OM
Bioorg Chem; 2018 Oct; 80():565-576. PubMed ID: 30025343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
